Oxybutynin Chloride Extended-Release Tablets

Type of Posting	Revision Bulletin
Posting Date	27–Oct–2017
Official Date	01–Nov–2017
Expert Committee	Chemical Medicines Monographs 3
Reason for Revision	Compliance

In accordance with the Rules and Procedures of the 2010-2015 Council of Experts, the Chemical Medicines Monograph 3 Expert Committee has revised the Oxybutynin Chloride Extended-Release Tablets monograph. The purpose of the revision is to add *Dissolution Test* 7 for a drug product approved by the FDA. This procedure was validated using a Zorbax RX-C8 brand of L7 column. The typical retention time for oxybutynin is about 4 minutes.

The Oxybutynin Chloride Extended Release Tablets Revision Bulletin supersedes the currently official monograph. The Revision Bulletin will be incorporated in the *Second Supplement to USP 41–NF 36*.

Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison (ba@usp.org).